Xospata 40 mg Tablet 21's

Xospata 40 mg Tablet 21's belongs to the group of medicines called protein kinase inhibitors used to treat acute myeloid leukaemia (AML) in adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation. Acute Myeloid Leukemia (AML) is a type of cancer that begins in the bone marrow, the spongy tissue responsible for producing blood cells. It is characterized by the abnormal production of myeloid cells, which disrupt the development of healthy blood cells.

Xospata 40 mg Tablet 21's contains Gilteritinib, which inhibits the activity of the enzyme FLT3 (FMS-like tyrosine kinase 3). This enzyme is crucial for the growth and survival of certain cancer cells. By blocking the activity of FLT3, gilteritinib helps stop the growth and division of cancer cells, leading to their death. This targeted approach makes gilteritinib an effective treatment for AML patients with FLT3 mutations.

Take Xospata 40 mg Tablet 21's as prescribed by your doctor. It may cause specific side effects such as fatigue, fever, mucositis (inflammation of the mucosa), oedema, rash, non-infectious diarrhoea, dyspnea (feeling short of breath), nausea, cough, constipation, headache, dizziness, and vomiting. While most side effects are temporary and resolve independently, it's essential to consult your doctor if they persist or worsen over time.

Inform your doctor about all the medications you are taking, if you are allergic to any of its ingredients and pre-existing medical conditions, if you have breathing or lung problems, irregular heartbeat, QT prolongation, posterior reversible encephalopathy syndrome, pancreatitis, severe renal impairment, or liver disease. Xospata 40 mg Tablet 21's is not recommended to use during pregnancy as it may harm your unborn baby, and not to breastfeed during treatment with Xospata 40 mg Tablet 21's for at least 2 months after the final dose. 

Xospata 40 mg Tablet 21's is used in the treatment of acute myeloid leukaemia (AML). The detailed uses of Xospata 40 mg Tablet 21's are as follows:

• Treatment of Acute Myeloid Leukemia (AML):Xospata 40 mg Tablet 21's helps slow the progression of leukemia by inhibiting cancer cell growth.
• Improves Survival Rates in AML Patients:Xospata 40 mg Tablet 21's is used in relapsed or refractory AML cases and helps control leukemia cell proliferation, improving treatment outcomes.

• Xospata 40 mg Tablet 21's can be taken with or without food.
• Follow your doctor’s instructions on the dosage and timing of this medication to ensure safe and effective use.
• Swallow Xospata 40 mg Tablet 21's as a whole with a glass of water.
• Do not crush, chew or break it.

Xospata 40 mg Tablet 21's belongs to the group of medicines called protein kinase inhibitors used to treat acute myeloid leukaemia (AML) in patients who are FLT3 mutation-positive by inhibiting cancer cell growth and improving survival rates. 

Inform your doctor about all the medications you are taking, if you are allergic to any of its ingredients and if you have pre-existing medical conditions. Also, inform your doctor if you have breathing or lung problems, hypokalemia (low blood potassium levels) or hypomagnesemia (low blood magnesium levels), irregular heartbeat, QT prolongation, posterior reversible encephalopathy syndrome (PRES), differentiation syndrome, pancreatitis, severe renal impairment, or liver disease. Xospata 40 mg Tablet 21's is not recommended to use during pregnancy as it may harm your unborn baby. Avoid breastfeeding during treatment with Xospata 40 mg Tablet 21's for at least 2 months after the final dose. Avoid consuming alcohol along with Xospata 40 mg Tablet 21's as it could lead to increased dizziness. Do not drive or use machines if you experience dizziness.